RxDoctor Payments Data

Ratnakar Pai, MD

Psychiatry · Detroit, MINPI 1740296045

Payments from drug & device makers

$1,227in general payments, 2019–2025

Across 37 payments — averaging $33.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$357
  • Johnson & Johnson$271
  • Neurocrine Biosciences, Inc.$124
  • E.r. Squibb & Sons, L.L.C.$121
  • Vanda Pharmaceuticals Inc.$104
  • Luye Pharma (USA) Ltd.$71
  • plus $179 from 5 others

What the payments were for

  • Food & beverage$1,227100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,227 in reported general payments places this provider in the 80th percentile of 1,166 psychiatry providers in Michigan.

See all psychiatry providers in Michigan

Medicare billing

Part B allowed, 2024
$19,729
Medicare patients
38
Services billed
242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole14$32,779
FanaptIloperidone13$27,809
TrintellixVortioxetine Hydrobromide43$21,286
Paliperidone ErPaliperidone56$19,577
Fluphenazine Hcl157$11,426
Lurasidone Hcl12$3,204
Aripiprazole70$2,894
Trazodone Hcl258$2,583
Clozapine24$2,152
Duloxetine Hcl90$1,938
Haloperidol Decanoate56$1,885
Haloperidol62$1,780
Buspirone Hcl162$1,723
Divalproex Sodium ErDivalproex Sodium46$1,604
Benztropine Mesylate197$1,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$67$32,77914 claims
Vanda Pharmaceuticals Inc.Fanapt$104$27,80913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,166 psychiatry providers in Michigan.

Other psychiatry in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →